Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s DiseaseRoland W. Bürli, Celia Dominguez, Ilka Müller et al.|Journal of Medicinal Chemistry|2013Cited by 149
Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitorChristopher A. Luckhurst, Celia Dominguez, Omar Aziz et al.|Bioorganic & Medicinal Chemistry Letters|2018Cited by 46
Quantifying autophagy using novel LC3B and p62 TR-FRET assaysAlberto Bresciani, Andreas Weiss, Maria Carolina Spiezia et al.|PLoS ONE|2018Cited by 45
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)Alberto Bresciani, Larry C. Park, Antonino Missineo et al.|Archives of Biochemistry and Biophysics|2017Cited by 45
Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 InteractionJesus M. Ontoria, Steven J. Harper, Ilaria Biancofiore et al.|ACS Medicinal Chemistry Letters|2020Cited by 29